Longeveron says ELPIS II trial of laromestrocel in hypoplastic left heart syndrome misses primary endpoint
LGVN•Strategic review launched
A strategic review was launched to maximize shareholder value, including plans to hire an investment bank and tighten spending.
ELPIS II trial misses primary endpoint
Longeveron reported topline results from its ELPIS II Phase 2b trial of laromestrocel in infants with hypoplastic left heart syndrome.
The study missed its main efficacy goal, raising uncertainty over the program’s near-term regulatory path.
Exploratory findings suggested potential benefits in longer-term outcomes, though the signals were not statistically conclusive.
Safety and tolerability remained consistent with prior studies, with no new safety issues flagged in the trial.
